Isoflavones Formula
Natural health product licensed in Canada
- Licence holder
- VSC Leader Source Products Co. Ltd.
- NPN or DIN-HM
- 80086905
- Status
- Active licence
- Licence date
- 6 July 2018
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Extrait d'isoflavones de trèfle rouge Source : Trifolium pratense- Feuille Potency : 8 % Isoflavones | 200 mg | Not calculated |
| Extrait d'isoflavone de soja Source : Glycine max - Graine Potency : 6.25 Milligrammes d'équivalents aglycones d'isoflavones Genistin | 50 mg | Not calculated |
| Extrait d'isoflavones de trèfle rouge Source : Trifolium pratense- Feuille | 16 Milligrammes d'équivalents aglycones d'isoflavones | Not calculated |
| Extrait d'isoflavone de soja Source : Glycine max - Graine Potency : 1.5 Milligrammes d'équivalents aglycones d'isoflavones Genistein | 15 Milligrammes d'équivalents aglycones d'isoflavones | Not calculated |
| Extrait d'isoflavone de soja Source : Glycine max - Graine Potency : 40 % Isoflavones | Not specified | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Gélatine, Maltodextrine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | minimum: 19 years | 1 Capsule | 2 days |
Uses authorised in Canada
Text supplied in English because no French text is available.
May reduce severe and frequent menopausal symptoms. Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80086905
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.